Actively Recruiting
Study of Metformin Treatment for Weight Loss in Obese Adults Without Diabetes, Ages 20 to 59
Led by University Of Nigeria Teaching Hospital · Updated on 2025-12-22
220
Participants Needed
2
Research Sites
26 weeks
Total Duration
AI-Summary
What this Trial Is About
Obesity is a major global health concern linked to heart disease, type 2 diabetes, and some cancers. This study is evaluating how metformin, a diabetes medication, affects weight loss, cardiovascular risk, and insulin resistance in obese Black Nigerian adults without diabetes. Researchers aim to understand metformins impact in this population, which may respond differently due to genetic and environmental factors. Participants will be randomly assigned to take either metformin extended release tablets, starting at 500 mg once daily and increasing up to 1500 mg daily, or a matching placebo that looks identical. The trial is blinded and placebo-controlled to fairly compare outcomes over two years. During the 24-month study, participants will have their weight, waist size, waist-to-hip ratio, cardiovascular risk, and insulin resistance regularly measured. Safety and medication adherence will be monitored throughout. This long-term follow-up will help determine metformins effects on obesity-related health measures in this population.
CONDITIONS
Brief Title
Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)
Research Team
C
Chiamaka C Onu, BSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
